Inflammatory insights into airway remodelling in asthma
CONCLUSIONS: Omalizumab is an effective therapy option in N-ERD patients in a 9 month study period. PMID: 32077449 [PubMed - as supplied by publisher]
ConclusionsThis large observational study based on claims data reliably identified subjects with COPD treated with open TT and their burden on the NHS. Moreover, it could describe the real clinical management of the open TT, before the marketing of the fixed one. These findings are useful for health policymakers in order to promote the appropriate utilization of both currently marketed and future therapies.
Publication date: Available online 21 February 2020Source: Pulmonary Pharmacology &TherapeuticsAuthor(s): Fang Yi, Lina Han, Baojuan Liu, Xu Zhang, Yongxin Xue, Wei Luo, Qiaoli Chen, Kefang LaiAbstractBackgroundNot all patients with cough variant asthma (CVA) show responsiveness to bronchodilators (RB) in clinic. Whether there are specific clinical and pathophysiological features can indicate RB in patients with CVA needs further investigation. Thus, we aimed to investigate the RB in patients with CVA and associated factors.MethodsForty-two CVA patients were randomized in a 2:1 ratio to receive oral bambuterol hydrochl...
ConclusionsFitness tracker sleep efficiency and wake counts demonstrate clinical utility as predictive of asthma-specific night-time wakening and daily FEV1. Fitness tracker sleep data demonstrated predictive capability for daily asthma outcomes.
Publication date: Available online 6 February 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Khalaf Kridin, Yael Renert-Yuval, Emma Guttman-Yassky, Arnon D. CohenBackgroundEvidence of TH1/IFN-γ overactivation as a major pathogenic driver somewhat conflicts with data supporting robust allergic background in patients with alopecia areata (AA). Previous investigations of immunological dysregulations show that both TH1- and TH2-related markers are overexpressed in AA. Clinical correlations in large populations may shed light on the immune pathways most likely to result in the clinical p...
As articles presented in this issue of the Annals make clear, our knowledge of eosinophilic esophagitis (EoE) is rapidly changing. Patients with EoE may already be present in our clinic or be referred to an allergist-immunologist from a gastroenterologist or other specialist for comanagement. It is critical that allergists-immunologists play a key role in the diagnosis and management of EoE.